Dynamic quotes: Off
|
Company Description (as filed with the SEC)
Oxygen Biotherapeutics is engaged in the business of developing biotechnology products with a focus on oxygen delivery to tissue. We are currently developing Oxycyte®, a product we believe is a safe and effective oxygen carrier for use acute medical situations. We have developed a family of perfluorocarbon-based oxygen carriers for use in personal care, topical wound healing, and other topical indications. In addition, we also have under development Vitavent™ (formerly called Fluorovent™), an oxygen exchange fluid for facilitating the treatment of lung conditions, and we have out-licensed our rights to a biosensor implant product that uses an enzyme process for measuring the glucose level in subcutaneous fluid. ... More ...
Analyst Info |
|
| Annual EPS Est: | $ |
| Quarterly EPS Est: | |
| PEG Ratio: | N/A |
|
Mean Recommendation: View Summary / View All |
|
Data is provided by Zacks Investment Research

